Conatus Pharmaceuticals Inc (NASDAQ:CNAT) – Stock analysts at FBR & Co lifted their Q1 2017 earnings per share (EPS) estimates for shares of Conatus Pharmaceuticals in a research note issued on Monday, according to Zacks Investment Research. FBR & Co analyst V. Bernardino now expects that the biotechnology company will post earnings per share of ($0.01) for the quarter, up from their previous forecast of ($0.22). FBR & Co currently has a “Outperform” rating and a $16.00 price objective on the stock. FBR & Co also issued estimates for Conatus Pharmaceuticals’ Q2 2017 earnings at $0.00 EPS, Q3 2017 earnings at ($0.01) EPS, Q4 2017 earnings at ($0.02) EPS, FY2017 earnings at ($0.05) EPS and FY2018 earnings at $2.71 EPS.
Several other equities research analysts also recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a research report on Friday, March 17th. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 14th. SunTrust Banks, Inc. restated a “buy” rating and set a $26.00 price objective (up from $17.00) on shares of Conatus Pharmaceuticals in a research report on Friday, December 23rd. Stifel Nicolaus restated a “buy” rating and set a $9.00 price objective (up from $7.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, March 16th. Finally, Aegis reiterated a “buy” rating and issued a $11.00 price target on shares of Conatus Pharmaceuticals in a research report on Thursday, March 16th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $13.25.
COPYRIGHT VIOLATION WARNING: “Conatus Pharmaceuticals Inc (CNAT) Expected to Earn Q1 2017 Earnings of ($0.01) Per Share” was published by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/q1-2017-eps-estimates-for-conatus-pharmaceuticals-inc-cnat-lifted-by-analyst-updated-updated/525486.html.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 0.462% on Thursday, reaching $7.545. The company’s stock had a trading volume of 1,189,913 shares. Conatus Pharmaceuticals has a 52-week low of $1.45 and a 52-week high of $8.05. The company has a 50 day moving average price of $5.43 and a 200 day moving average price of $3.82. The company’s market cap is $197.45 million.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.03. The firm earned $0.80 million during the quarter. During the same quarter in the prior year, the business earned ($0.30) EPS.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in shares of Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 121,100 shares in the last quarter. Courage Capital Management LLC purchased a new position in shares of Conatus Pharmaceuticals during the third quarter valued at approximately $200,000. Ellington Management Group LLC purchased a new position in shares of Conatus Pharmaceuticals during the fourth quarter valued at approximately $154,000. ING Groep NV purchased a new position in shares of Conatus Pharmaceuticals during the fourth quarter valued at approximately $110,000. Finally, United Capital Financial Advisers LLC increased its position in shares of Conatus Pharmaceuticals by 5.7% in the fourth quarter. United Capital Financial Advisers LLC now owns 154,578 shares of the biotechnology company’s stock valued at $815,000 after buying an additional 8,369 shares in the last quarter. Institutional investors and hedge funds own 15.90% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with our FREE daily email newsletter.